Reference

1. Vishal, T., and Rahul, M. (2022), “Novel Therapeutic Target(s) for Psoriatic Disease.” Frontiers in Medicine, 9: 1-12.
2. Augustin, M., and Radtke, M. A. (2014), “Quality of life in psoriasis patients.” Expert Rev Pharmacoecon Outcomes Res, 14: 559– 568.
3. Davidovici, B. B., Sattar, N., Prinz, J., Puig, L., Emery, P., and Barker, J., N. (2010), “Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.” J Invest Dermatol, 130: 1785– 1796.
4. Hawkes, J. E., Chan, T. C., and Krueger, J. G. (2017), “Psoriasis pathogenesis and the development of novel targeted immune therapies.” J Allergy Clin Immunol, 140: 645– 653.
5. Antony, R., Satveer, K. M., and Jonathan, N. B. (2021), “Psoriasis: a brief overview.” Clinical Medicine, 21(3): 170–173.
6. Dand, N., Mahil, S. K., and Capon, F. (2020), “Psoriasis and genetics.” Acta Derm Venereol, 100: adv00030.
7. Budu-Aggrey, A., Brumpton, B., and Tyrrell, J. (2019), “Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study.” PLoS Med, 16: e1002739.
8. Onoufriadis, A., Simpson, M. A., Pink, A. E. (2011), “Mutations in IL36RN/ IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.” Am J Hum Genet, 89: 432–437.
9. Winterfield, L. S., Menter, A., Gordon, K., and Gottlieb A. (2005), “Psoriasis treatment: current and emerging directed therapies.” Ann Rheum Dis, 64(Suppl II): ii87–ii90.
10. Aishwarya, P., Bhagwat, B. M. (2023), “The Current Advancement in Psoriasis.” Cureus, 15(10): e47006.
11. Bachelez H. (2020), “Pustular psoriasis: the dawn of a new era.” Acta Derm Venereol,  100: 87-92
12. Langley, R. G. B., Krueger, G. G., and Griffiths, C. E. M. (2005), “Psoriasis: epidemiology, clinical features, and quality of life.” Ann Rheum Dis, 64(Suppl II): ii18–ii23.
13. Salgado-Boquete, L., Carrascosa, J.M., Llamas-Velasco, M., Ruiz-Villaverde, R., de la Cueva, P., and Belinchón, I. (2021), “A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis.” Life, 11: 627.
14. Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E., Nast, A., Franke, J., Antoniou, C., Arenberger, P., and Balieva, F. (2011), “Definition of treatment goals for moderate to severe psoriasis: A European consensus.” Arch. Dermatol. Res., 303: 1–10.
15. Oranje, A. P., Marcoux, D., Svensson, A., Prendiville, J., Krafchik, B., Toole, J., Rosenthal, D., de Waard-van der Spek, F.B., Molin, L., and Axelsen, M. (1997), “Topical calcipotriol in childhood psoriasis.” J. Am. Acad. Dermatol, 36: 203–208.
16. Maul, J. T., Anzengruber, F., Conrad, C., Cozzio, A., Häusermann, P., Jalili, A., Kolios, A.G.A., Laffitte, E., Lapointe, A. K., and Mainetti, C. (2021), “Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.” Dermatology, 237: 166–178
17. Elmets, C. A., Korman, N. J., Prater, E. F., Wong, E. B., Rupani, R. N., Kivelevitch, D., Armstrong, A.W., Connor, C., Cordoro, K.M., and Davis, D.M.R. (2021), “Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.” J. Am. Acad. Dermatol, 84: 432–470.
18. Blauvelt, A., Leonardi, C.L., Gooderham, M., Papp, K.A., Philipp, S., Wu, J.J., Igarashi, A., Flack, M., Geng, Z., and Wu, T. (2020), “Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.” JAMA Dermatol, 156: 649–658.
19. Gold, L.S., Lebwohl, M.G., Sugarman, J.L., Pariser, D.M., Lin, T., Martin, G., Pillai, R., Israel, R., and Ramakrishna, T. (2018), “Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.” J. Am. Acad. Dermatol, 79: 287–293.
20. Lis-Swiety, A., and Fratczak, A. (2022), “Proactive therapy: New perspectives for long-term topical treatment of psoriasis.” Dermatol. Ther, 35: e15364.
21. Hyun-Ji, L., and Miri K. (2023), “Challenges and Future Trends in the Treatment of Psoriasis.” Int. J. Mol. Sci, 24(13313): 1-12.
22. Elmets, C.A., Lim, H.W., Stoff, B., Connor, C., Cordoro, K.M., Lebwohl, M., Armstrong, A.W., Davis, D.M.R., Elewski, B.E., and Gelfand, J.M. (2019), “Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.” J. Am. Acad. Dermatol, 81: 775–804.
23. Menter, A., Gelfand, J.M., Connor, C., Armstrong, A.W., Cordoro, K.M., Davis, D.M.R., Elewski, B.E., Gordon, K.B., Gottlieb, A.B., and Kaplan, D.H. (2020), “Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.” J. Am. Acad. Dermatol, 82: 1445–1486.
24. López-Ferrer, A., Vilarrasa, E., and Puig, L. (2015), “Secukinumab (AIN457) for the treatment of psoriasis.” Expert Rev. Clin. Immunol, 11: 1177–1188.
25. Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., and Erickson, J. (2018), “Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).” Br. J. Dermatol, 178: 674–681.
26. Foulkes, A.C., and Warren, R.B. (2019), “Brodalumab in psoriasis: Evidence to date and clinical potential.” Drugs Context, 8: 212570.
27. Reich, K., Leonardi, C., Langley, R.G., Warren, R.B., Bachelez, H., Romiti, R., Ohtsuki, M., Xu, W., Acharya, N., and Solotkin, K. (2017), “Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.” J. Am. Acad. Dermatol, 76: 441–448.
28. Dávila-Seijo, P., Dauden, E., Descalzo, M.A., Carretero, G., Carrascosa, J.M., Vanaclocha, F., Gómez-García, F.J., De la Cueva-Dobao, P., Herrera-Ceballos, E., and  Belinchón, I. (2017), “Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the Biobadaderm Registry.” J. Investig. Dermatol, 137: 313–321.
29. Beck, K.M., and Koo, J. (2019), “Brodalumab for the treatment of plaque psoriasis: Up-to-date.” Expert Opin. Biol. Ther, 19: 287–292.
30. Blauvelt, A., Kimball, A.B., Augustin, M., Okubo, Y., Witte, M.M., Capriles, C.R., Sontag, A., Arora, V., Osuntokun, O., and Strober, B. (2022), “Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).” Br. J. Dermatol, 187: 866–877.
31. Krueger, J.G., McInnes, I.B., and Blauvelt, A. (2022), “Tyrosine kinase 2 and Janus kinase–signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.” J. Am. Acad. Dermatol, 86: 148–157.
32. Zhang, L., Guo, L., Wang, L., and Jiang, X. (2022), “The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis—A network meta-analysis.” J. Eur. Acad. Dermatol. Venereol, 36: 1937–1946.
33. Strober, B., Thaçi, D., Sofen, H., Kircik, L., Gordon, K.B., Foley, P., Rich, P., Paul, C., Bagel, J., and Colston, E. (2023), “Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial.” J. Am. Acad. Dermatol, 88: 40–51
34. Tang, L., Yang, X., Liang, Y., Xie, H., Dai, Z., and Zheng, G. (2018), “Transcription factor retinoidrelated orphan receptor ?t: a promising target for the treatment of psoriasis.” Front Immunol, 9: 1210.
35. Pandya, V. B., Kumar, S., Sachchidanand., Sharma, R., Desai, R. C. (2018), “Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-? (ROR? or RORc) Inhibitors: Hits and Misses.” J Med Chem, 61: 10976– 10995.
36. Imura, C., Ueyama, A., Sasaki, Y., Shimizu, M., Furue, Y., and Tai N. (2019), “A novel ROR?t inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations.” J Dermatol Sci, 93: 176–185.
37. Jacobson, K. A., Merighi, S., Varani, K., Borea, P.A., Baraldi, S., and Aghazadeh, T. M. (2018), “A(3) adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy.” Med Res Rev, 38: 1031– 1072.
38. Cohen, S., Barer, F., Itzhak, I., Silverman, M. H., and Fishman, P. (2018), “Inhibition of IL-17 and IL-23 in human keratinocytes by the A(3) adenosine receptor agonist piclidenoson.” J Immunol Res, 2018: 2310970.